Hepatitis B Virus Prevalence and Risk Factors in Belgium

Hepatitis B Clinical Trial

— HBVBE  

Official title:

Hepatitis B Virus Prevalence and Risk Factors in Middle Limburg Belgium: the Importance of Migration.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03425513
• Other study ID #: HBVBE
• Status: Completed
• Start date: May 12, 2017
• Est. completion date: November 27, 2017

Study information

• Verified date: January 2020
• Source: Hasselt University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study was to evaluate the current prevalence and risk factors of hepatitis B virus (HBV) infection in a multi-ethnic neighbourhood situated in Middle Limburg, Belgium. Additionally, the investigators will determine linkage of care in hepatitis B surface antigen (HBsAg) positive subjects.

Description:

Although the HBV prevalence is generally low in Western countries, such as Belgium, pockets of higher HBV prevalence exist in areas with large immigrant populations. Therefore national prevalence figures can underestimate the burden of HBV infection. The prevalence of chronic HBV in the population-based study in 2003 is believed to be an underestimate due to under-representation of the non-Belgian population. Moreover, by this time there are no data regarding the risk factors for HBV infection in the general population of Belgium.

Even in low-prevalence areas such as Belgium, HBV prevention and control is a public health priority, particularly since safe and effective vaccines are available. The aim of this study was to evaluate the current prevalence and risk factors of HBV infection in a multi-ethnic neighbourhood situated in Middle Limburg, Belgium. Additionally, the investigators will determine linkage of care in hepatitis B surface antigen (HBsAg) positive subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1131
• Est. completion date: November 27, 2017
• Est. primary completion date: November 27, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 70

• Males and females

Exclusion Criteria:

/

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B

Intervention

Diagnostic Test:
• Hepatitis B serology
A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).

Other:
• Questionnaire
Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.

Locations

Country	Name	City	State
Belgium	Ziekenhuis Oost-Limburg	Genk	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Hasselt University

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroprevalence of current HBV infection in the Middle Limburg population	Serum HBsAg	1 day
Primary	Seroprevalence of past or current HBV infection in the Middle Limburg population	Serum anti-HBc antibodies	1 day
Secondary	Assess risk factors for current HBV infection in the Middle Limburg population	Combine results from (1) serum HBsAg with (2) questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.	1 day
Secondary	Assess risk factors for past or current HBV infection in the Middle Limburg population	Combine results from (1) serum anti-HBc antibodies with (2) questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.	1 day